The panel, which consisted of antimicrobial drug experts, recommended molnupiravir be authorized to treat people with COVID-19 who are at high risk of severe disease. The vote was narrower than expected at 13-10.
Panel members who voted against the drug’s approval were concerned about its safety, efficacy and whether it would facilitate the virus’s mutation into more dangerous variants, according to CNBC.
On Nov. 26, Merck released a final analysis of the drug showing it reduced the risk of hospitalization or death among high-risk patients by about 30 percent, down from 48 percent in an earlier analysis.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.